Eiger BioPharmaceuticals reports second quarter 2018 financial results
Eiger BioPharma reported the net loss for the 2018 second quarter was $9.9 million, or $0.82 per share basic and diluted, versus a net loss of $11.1 million, or $1.33 per share basic and diluted for the prior year period. On and short-term debt securities of $73.5 million. August 10, 2018